SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer
Francois Clement Bidard, Carlos Barrios, Giampaolo Bianchini, Adam Brufsky et autres
In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key …
fr, br, it, us, ca, es, ae, de, be, jp, au, gb, kr, ch (code pays fourni par la source)